|
1
|
Mizushima N: Physiological functions of
autophagy. Curr Top Microbiol Immunol. 335:71–84. 2009.PubMed/NCBI
|
|
2
|
Mathew R, Karantza-Wadsworth V and White
E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eskelinen EL: The dual role of autophagy
in cancer. Curr Opin Pharmacol. 11:294–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Degenhardt K, Mathew R, Beaudoin B, et al:
Autophagy promotes tumor cell survival and restricts necrosis,
inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amaravadi RK, Lippincott-Schwartz J, Yin
XM, et al: Principles and current strategies for targeting
autophagy for cancer treatment. Clin Cancer Res. 17:654–666. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qadir MA, Kwok B, Dragowska WH, et al:
Macroautophagy inhibition sensitizes tamoxifen-resistant breast
cancer cells and enhances mitochondrial depolarization. Breast
Cancer Res Treat. 112:389–403. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wiley SR, Schooley K, Smolak PJ, et al:
Identification and characterization of a new member of the TNF
family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ashkenazi A, Pai RC, Fong S, et al: Safety
and antitumor activity of recombinant soluble Apo2 ligand. J Clin
Invest. 104:155–162. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Walczak H, Miller RE, Ariail K, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mahalingam D, Szegezdi E, Keane M, de Jong
S and Samali A: TRAIL receptor signalling and modulation: are we on
the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abdulghani J and El-Deiry WS: TRAIL
receptor signaling and therapeutics. Expert Opin Ther Targets.
14:1091–1108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Menke C, Bin L, Thorburn J, Behbakht K,
Ford HL and Thorburn A: Distinct TRAIL resistance mechanisms can be
overcome by proteasome inhibition but not generally by synergizing
agents. Cancer Res. 71:1883–1892. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Keane MM, Ettenberg SA, Nau MM, Russell EK
and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in
breast cell lines. Cancer Res. 59:734–741. 1999.PubMed/NCBI
|
|
15
|
Yoshida T, Zhang Y, Rivera Rosado LA and
Zhang B: Repeated treatment with subtoxic doses of TRAIL induces
resistance to apoptosis through its death receptors in MDA-MB-231
breast cancer cells. Mol Cancer Res. 7:1835–1844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rahman M, Davis SR, Pumphrey JG, et al:
TRAIL induces apoptosis in triple-negative breast cancer cells with
a mesenchymal phenotype. Breast Cancer Res Treat. 113:217–230.
2009. View Article : Google Scholar :
|
|
17
|
Bossen C, Tardivel A, Willen L, et al:
Mutation of the BAFF furin cleavage site impairs B-cell homeostasis
and antibody responses. Eur J Immunol. 41:787–797. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim SH, Kim K, Kwagh JG, et al: Death
induction by recombinant native TRAIL and its prevention by a
caspase 9 inhibitor in primary human esophageal epithelial cells. J
Biol Chem. 279:40044–40052. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Biederbick A, Kern HF and Elsässer HP:
Monodansylcadaverine (MDC) is a specific in vivo marker for
autophagic vacuoles. Eur J Cell Biol. 66:3–14. 1995.PubMed/NCBI
|
|
20
|
Mariño G, Ugalde AP, Salvador-Montoliu N,
et al: Premature aging in mice activates a systemic metabolic
response involving autophagy induction. Hum Mol Genet.
17:2196–2211. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang N, Wang X, Huo Q, et al: The
oncogene metadherin modulates the apoptotic pathway based on the
tumor necrosis factor superfamily member TRAIL (Tumor Necrosis
Factor-related Apoptosis-inducing Ligand) in breast cancer. J Biol
Chem. 288:9396–9407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klionsky DJ and Emr SD: Autophagy as a
regulated pathway of cellular degradation. Science. 290:1717–1721.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kelekar A: Introduction to the review
series Autophagy in Higher Eukaryotes - a matter of survival or
death. Autophagy. 4:555–556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pankiv S, Clausen TH, Lamark T, et al:
p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of
ubiquitinated protein aggregates by autophagy. J Biol Chem.
282:24131–24145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Valentim L, Laurence KM, Townsend PA, et
al: Urocortin inhibits Beclin1-mediated autophagic cell death in
cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol
Cell Cardiol. 40:846–852. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mizushima N, Yoshimori T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sternberg CN, Donat SM, Bellmunt J, et al:
Chemotherapy for bladder cancer: treatment guidelines for
neoadjuvant chemotherapy, bladder preservation, adjuvant
chemotherapy, and metastatic cancer. Urology. 69(Suppl 1): S62–S79.
2007. View Article : Google Scholar
|
|
28
|
Yang ZJ, Chee CE, Huang S and Sinicrope
FA: The role of autophagy in cancer: therapeutic implications. Mol
Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
|
